Cécile Matthews and Bhavesh Patel were quoted in Pink Sheet regarding their analysis entitled “How do rare disease patient numbers in Germany affect prices for non-oncology orphan drugs?” In Pink Sheet, Matthews and Patel discuss factors to consider when agreeing on a price including benefit ratings, patient populations, and budget impact.
CRA presents at AXS25 "GLP-1s: Riding the Wave of Innovative Medications"
Read the key takeaways here.